INDEPENDENT

BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the first quarter ended March 31, 2015....

BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2015....

Dyax Corp. (NASDAQ: DYAX) will release third quarter financial results onWednesday, October 28, 2015 after market close. In lieu of the...

BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the second quarter ended June 30, 2015....

Preclinical Data Support Thesis That Factor XIIa Inhibition Has the Potential to be an Effective Antithrombotic, Without Bleeding Side...

Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Jefferies 2015 Global Healthcare Conference being...

Company to Review Third Quarter 2015 Financial Results as Part of R&D Day
Dyax Corp. (NASDAQ: DYAX) will host a Research and Development...

BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Morgan Stanley...

ONIVYDE, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), is the first and only treatment approved for this patient...

DUBLIN and BURLINGTON, Massachusetts, November 2, 2015 /PRNewswire/ --DX-2930 has potential to expand HAE-treated patients and achieve annual...